Therapeutic Classification

typical antipsychotic Registry

Clinical reference for typical antipsychotic medications. Access safety monographs, dosing adjustments, and drug-drug interactions for all registered brand names and generics in this class.

Registered Medications (typical antipsychotic)

Medication	Therapeutic Class	Maternal Safety
ARIPIPRAZOLE Strong CYP3A4 inhibitors (eg ketoconazole) or inducers (eg carbamazepine) require dose adjustment May cause suicidal thoughts and metabolic changes including weight gain and dyslipidemia.	Atypical Antipsychotic	safe
ASENAPINE MALEATE Strong CYP1A2 inhibitors like fluvoxamine increase asenapine levels Sublingual administration food and drink can decrease absorption May cause cerebrovascular events in elderly patients with dementia.	Atypical Antipsychotic	safe
BREXPIPRAZOLE Strong CYP3A4 or CYP2D6 inhibitors require dose adjustment May cause suicidal thoughts and metabolic changes including weight gain and dyslipidemia.	Atypical Antipsychotic	safe
CLOZAPINE Bone marrow suppressants may increase risk of agranulocytosis Can cause severe neutropenia and agranulocytosis requiring mandatory WBC monitoring.	Atypical Antipsychotic	safe
FLUPHENAZINE CNS depressants may enhance sedative effects Can cause extrapyramidal symptoms and neuroleptic malignant syndrome.	Typical Antipsychotic	safe
FLUPHENAZINE DECANOATE CNS depressants may enhance sedative effects Can cause extrapyramidal symptoms and neuroleptic malignant syndrome.	Typical Antipsychotic	safe
FLUPHENAZINE HCL CNS depressants may enhance sedative effects Can cause extrapyramidal symptoms and neuroleptic malignant syndrome.	Typical Antipsychotic	safe
FLUPHENAZINE HYDROCHLORIDE CNS depressants may enhance sedative effects Can cause extrapyramidal symptoms and neuroleptic malignant syndrome.	Typical Antipsychotic	safe
HALOPERIDOL DECANOATE CNS depressants may enhance sedative effects Can cause extrapyramidal symptoms and QT prolongation.	Typical Antipsychotic	safe
HALOPERIDOL INTENSOL CNS depressants may enhance sedative effects Can cause extrapyramidal symptoms and QT prolongation.	Typical Antipsychotic	safe
HALOPERIDOL LACTATE CNS depressants may enhance sedative effects Can cause extrapyramidal symptoms and QT prolongation.	Typical Antipsychotic	safe
ILOPERIDONE Strong CYP2D6 or CYP3A4 inhibitors require dose adjustment Can cause orthostatic hypotension and QT prolongation.	Atypical Antipsychotic	safe
LURASIDONE HYDROCHLORIDE Strong CYP3A4 inhibitors and inducers are contraindicated Can cause somnolence and akathisia.	Atypical Antipsychotic	safe
OLANZAPINE AND FLUOXETINE HYDROCHLORIDE CNS depressants may enhance sedative effects Can cause metabolic changes including weight gain hyperlipidemia and hyperglycemia.	Atypical Antipsychotic	safe
PALIPERIDONE Strong CYP3A4 or P-gp inducers may decrease levels Can cause QT prolongation and orthostatic hypotension.	Atypical Antipsychotic	safe
PALIPERIDONE PALMITATE Strong CYP3A4 or P-gp inducers may decrease levels Can cause QT prolongation and orthostatic hypotension.	Atypical Antipsychotic	safe
PERPHENAZINE CNS depressants may enhance sedative effects Can cause extrapyramidal symptoms and neuroleptic malignant syndrome.	Typical Antipsychotic	safe
PERPHENAZINE AND AMITRIPTYLINE HYDROCHLORIDE CNS depressants may enhance sedative effects Can cause extrapyramidal symptoms and neuroleptic malignant syndrome.	Typical Antipsychotic	safe
PIMOZIDE Strong CYP3A4 inhibitors are contraindicated due to risk of QT prolongation Can cause QT prolongation and extrapyramidal symptoms.	Typical Antipsychotic	safe
PROCHLORPERAZINE CNS depressants may enhance sedative effects Can cause extrapyramidal symptoms and neuroleptic malignant syndrome.	Typical Antipsychotic / Antiemetic	safe
PROCHLORPERAZINE EDISYLATE CNS depressants may enhance sedative effects Can cause extrapyramidal symptoms and neuroleptic malignant syndrome.	Typical Antipsychotic / Antiemetic	safe
PROCHLORPERAZINE MALEATE CNS depressants may enhance sedative effects Can cause extrapyramidal symptoms and neuroleptic malignant syndrome.	Typical Antipsychotic / Antiemetic	safe
Quetiapine Atypical antipsychotic used for schizophrenia, bipolar disorder, and as an adjunct in treatment-resistant depression. Registry data and cohort studies involving thousands of first-trimester exposures do not demonstrate a consistent pattern of major congenital malformations. However, neonates exposed near delivery can develop extrapyramidal symptoms and neonatal withdrawal syndrome. Associated with gestational diabetes due to metabolic effects. Untreated psychosis or bipolar disorder in pregnancy carries serious maternal and fetal risks.	Atypical Antipsychotic	caution
QUETIAPINE FUMARATE Strong CYP3A4 inhibitors may increase levels Can cause sedation cataracts and metabolic changes.	Atypical Antipsychotic	safe
RISPERIDONE Strong CYP2D6 inhibitors may increase levels Can cause hyperprolactinemia and metabolic changes.	Atypical Antipsychotic	safe
THIORIDAZINE HYDROCHLORIDE Strong CYP2D6 inhibitors are contraindicated due to risk of QT prolongation Can cause QT prolongation and retinopathy.	Typical Antipsychotic	safe
THIORIDAZINE HYDROCHLORIDE INTENSOL Strong CYP2D6 inhibitors are contraindicated due to risk of QT prolongation Can cause QT prolongation and retinopathy.	Typical Antipsychotic	safe
TRIFLUOPERAZINE HCL CNS depressants may enhance sedative effects Can cause extrapyramidal symptoms and neuroleptic malignant syndrome.	Typical Antipsychotic	safe
TRIFLUOPERAZINE HYDROCHLORIDE CNS depressants may enhance sedative effects Can cause extrapyramidal symptoms and neuroleptic malignant syndrome.	Typical Antipsychotic	safe
ZIPRASIDONE HYDROCHLORIDE Other drugs that prolong the QT interval are contraindicated Can cause QT prolongation and rash.	Atypical Antipsychotic	safe
ZIPRASIDONE MESYLATE Other drugs that prolong the QT interval are contraindicated Can cause QT prolongation and rash.	Atypical Antipsychotic	safe

This therapeutic registry is dynamically synthesized from professional clinical sources. Listing of a medication does not imply equivalence; refer to individual monographs for head-to-head pharmacological data.